Sunshine Biopharma Stock Buy Hold or Sell Recommendation
| SBFM Stock | USD 2.36 0.24 11.32% |
Given the investment horizon of 90 days and your below-average risk tolerance, our recommendation regarding Sunshine Biopharma is 'Strong Sell'. The recommendation algorithm takes into account all of Sunshine Biopharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Sunshine Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide. Note, we conduct extensive research on individual companies such as Sunshine and provide practical buy, sell, or hold advice based on investors' constraints. Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
Sunshine |
Execute Sunshine Biopharma Buy or Sell Advice
The Sunshine recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sunshine Biopharma. Macroaxis does not own or have any residual interests in Sunshine Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sunshine Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Sunshine Biopharma Trading Alerts and Improvement Suggestions
| Sunshine Biopharma generated a negative expected return over the last 90 days | |
| Sunshine Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 1.7 M. | |
| Sunshine Biopharma currently holds about 41.74 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21. | |
| Sunshine Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Sunshine Biopharma Reports 2024 Third Quarter Results Year-To-Date Revenues Up 54 |
Sunshine Biopharma Returns Distribution Density
The distribution of Sunshine Biopharma's historical returns is an attempt to chart the uncertainty of Sunshine Biopharma's future price movements. The chart of the probability distribution of Sunshine Biopharma daily returns describes the distribution of returns around its average expected value. We use Sunshine Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sunshine Biopharma returns is essential to provide solid investment advice for Sunshine Biopharma.
| Mean Return | -0.47 | Value At Risk | -6.29 | Potential Upside | 5.90 | Standard Deviation | 3.57 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sunshine Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sunshine Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Sunshine Biopharma, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Sunshine Biopharma back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Nordwand Advisors Llc | 2024-09-30 | 500 | Main Street Group Ltd | 2024-06-30 | 3.0 | Rise Advisors, Llc | 2024-09-30 | 1.0 | Jaffetilchin Investment Partners, Llc | 2024-09-30 | 1.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Royal Bank Of Canada | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-06-30 | 0.0 | Bridgeway Capital Management, Llc | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 |
Sunshine Biopharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (74.7K) | 949.4K | 1.1M | 19.8M | (5.5M) | (5.3M) | |
| Free Cash Flow | (496.7K) | (658.5K) | (1.8M) | (5.6M) | (9.6M) | (9.1M) | |
| Other Non Cash Items | 1.2M | 2.2M | 10.7M | 18.3M | 4.6M | 3.7M | |
| Capital Expenditures | 18.9K | 860.0 | 1.2K | 305.0K | 788.1K | 827.5K | |
| Net Income | (1.7M) | (2.8M) | (12.4M) | (26.7M) | (4.5M) | (4.7M) | |
| End Period Cash Flow | 40.5K | 989.9K | 2.0M | 21.8M | 16.3M | 17.1M | |
| Net Borrowings | 500.9K | 416.5K | 1.6M | 2.9M | 3.3M | 3.5M | |
| Depreciation | 13.8K | 14.1K | 12.7K | 25.2K | 149.1K | 156.6K | |
| Change To Netincome | 1.2M | 2.2M | 10.7M | 18.3M | 21.1M | 22.1M | |
| Investments | (15.3K) | (1.2K) | (391.0) | (14.6M) | (15.0M) | (14.3M) |
Sunshine Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sunshine Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sunshine Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sunshine stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 0.67 | |
σ | Overall volatility | 3.76 | |
Ir | Information ratio | -0.16 |
Sunshine Biopharma Volatility Alert
Sunshine Biopharma exhibits very low volatility with skewness of 0.27 and kurtosis of 0.99. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Sunshine Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Sunshine Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Sunshine Biopharma Fundamentals Vs Peers
Comparing Sunshine Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sunshine Biopharma's direct or indirect competition across all of the common fundamentals between Sunshine Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sunshine Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sunshine Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sunshine Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sunshine Biopharma to competition |
| Fundamentals | Sunshine Biopharma | Peer Average |
| Return On Equity | -0.18 | -0.31 |
| Return On Asset | -0.11 | -0.14 |
| Profit Margin | (0.13) % | (1.27) % |
| Operating Margin | (0.13) % | (5.51) % |
| Current Valuation | (7.4 M) | 16.62 B |
| Shares Outstanding | 2 M | 571.82 M |
| Shares Owned By Insiders | 0.23 % | 10.09 % |
| Shares Owned By Institutions | 1.84 % | 39.21 % |
| Number Of Shares Shorted | 374.13 K | 4.71 M |
| Price To Earning | 1.07 X | 28.72 X |
| Price To Book | 0.17 X | 9.51 X |
| Price To Sales | 0.13 X | 11.42 X |
| Revenue | 24.09 M | 9.43 B |
| Gross Profit | 1.7 M | 27.38 B |
| EBITDA | (3.82 M) | 3.9 B |
| Net Income | (4.51 M) | 570.98 M |
| Cash And Equivalents | 41.74 M | 2.7 B |
| Cash Per Share | 2.21 X | 5.01 X |
| Total Debt | 657.71 K | 5.32 B |
| Debt To Equity | 8.98 % | 48.70 % |
| Current Ratio | 401.11 X | 2.16 X |
| Book Value Per Share | 12.52 X | 1.93 K |
| Cash Flow From Operations | (8.78 M) | 971.22 M |
| Short Ratio | 4.13 X | 4.00 X |
| Earnings Per Share | (127.90) X | 3.12 X |
| Target Price | 300.0 | |
| Number Of Employees | 44 | 18.84 K |
| Beta | -1.04 | -0.15 |
| Market Capitalization | 4.24 M | 19.03 B |
| Total Asset | 27.35 M | 29.47 B |
| Retained Earnings | (63.91 M) | 9.33 B |
| Working Capital | 19.34 M | 1.48 B |
| Current Asset | 23 K | 9.34 B |
Note: Acquisition by Camille Sebaaly of 14000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 [view details]
Sunshine Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sunshine . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 8.1 M | |||
| Daily Balance Of Power | 0.2609 | |||
| Rate Of Daily Change | 1.11 | |||
| Day Median Price | 2.58 | |||
| Day Typical Price | 2.51 | |||
| Price Action Indicator | (0.10) | |||
| Period Momentum Indicator | 0.24 |
About Sunshine Biopharma Buy or Sell Advice
When is the right time to buy or sell Sunshine Biopharma? Buying financial instruments such as Sunshine Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Sunshine Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Railroads Thematic Idea Now
Railroads
Companies involved in manufacturing and maintenance of freight railroads and passenger trains as well as providing railroad services to public. The Railroads theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Railroads Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sunshine Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.